Tempest Therapeutics Inc
Research Tempest Therapeutics Inc (TPST) on Bullrun: market cap USD 16.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTPST
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.44M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 43.10M
- Free cash flow-USD 7.60M
Valuation Snapshot
latest market cap is USD 16.44M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.26M | -USD 26.82M | n/a | -6.33 | USD 7.71M | USD 0 | USD 6.67M |
| FY2024 | USD 0 | -USD 41.84M | -USD 33.46M | n/a | -19.5 | USD 30.27M | USD 6.35M | USD 19.13M |
| FY2023 | n/a | -USD 29.49M | -USD 27.53M | n/a | -1.91 | USD 39.23M | USD 10.55M | USD 26.77M |
| FY2022 | n/a | -USD 35.71M | -USD 31.63M | n/a | -3.09 | USD 31.23M | USD 10.37M | USD 18.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.44M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 14.14M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 36.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 84.69M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.09M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 36.49M | n/a | n/a | n/a |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tempest Therapeutics Inc's market cap?
Tempest Therapeutics Inc's market capitalization is USD 16.44M.
What does Tempest Therapeutics Inc do?
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd.